Of all 11 RCTs, 4 were BRCA mutation-correlated; 6 used the PARP inhibitor Olaparib, 4 used Iniparib, and 1 used Veliparib; 4 were about ovarian cancer, 2 about lung cancer, 2 about breast cancer, 1 about gastric cancer, 1 about pancreatic cancer, and 1 about ovarian, peritoneal, and fallopian tube cancers. This evidence concerns the gene PARP1 and breast carcinoma.